Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
12 nov. 2024 08h00 HE
|
Compass Therapeutics
Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first...
Crescent Innovations Inc. Reports That Inquiries Surrounding Sale of Its Bone Repair Technology Are Increasing
29 août 2024 08h00 HE
|
Crescent Innovations Inc.
Crescent Innovations Inc. reports that inquires surrounding sale of its bone repair technology are increasing.
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
13 mai 2024 08h00 HE
|
Compass Therapeutics
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
12 avr. 2024 08h00 HE
|
Compass Therapeutics
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
21 mars 2024 09h00 HE
|
Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
01 févr. 2024 01h03 HE
|
F. Hoffmann-La Roche Ltd
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...
Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes
22 juin 2023 16h05 HE
|
Compass Therapeutics
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023
07 févr. 2023 07h05 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Zhittya Genesis Medicine announces: Free Zoom Webinar: Zhittya Parkinson’s Disease Research Study: 6-Month Patient Follow-Up Report
19 déc. 2022 12h00 HE
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on Tuesday, December 20, 2022, at 4:00 PM...
Zhittya Genesis Medicine - Parkinson’s Disease and Other Brain Disorders: Is FGF-1 a Novel Breakthrough Medical Treatment
25 oct. 2022 10h00 HE
|
Zhittya Genesis Medicine Inc
Invitation to a Free Luncheon Presentation in Jeddah, Saudi Arabia, on Monday, October 31, 2022, at 1:00 pm (13:00) View Preliminary Human Data after 30 Days Treatment of Parkinson’s Disease Patients...